Semaglutide – medicarereport.org

Thursday, November 21, 2024

Latest:

Employer Healthcare Health Care - General Health Insurance Medicaid Medicare - General Part D/Prescription Drugs

Eileen Cook August 14, 2024August 14, 2024 Commercial Health Insurance, Employer Health Insurance, Healthcare Costs, Healthcare Finance, Medicaid, medicare, Ozempic, Semaglutide

Majority of weight loss drug prescriptions going to commercially insured patients

(By Jakob Emerson for Becker’s Hospital Review) In 2023, more than 61% of Ozempic prescriptions went to patients with commercial

CMS Emerging Health Issues Health Care Finance Medicare - General

Eileen Cook May 17, 2024 CMS, GLP-1s drugs, Healthcare Finance, medicare, Medicare Part D, Older Adults, Semaglutide

Medicare spending on weight loss drugs may be lower than previously thought: Report

(By Rylee Wilson for Becker’s Hospital Review) Medicare spending on GLP-1 medications may not be as high as some estimates predict

CMS Medicare - General Part D/Prescription Drugs

Eileen Cook April 29, 2024April 29, 2024 CMS, FDA, medicare, Medicare Part D, Older Adults, Reduce Heart Risk, Semaglutide, Wegovy

An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk

(By Chris Lee for The Kaiser Family Foundation published April 24, 2024) In a new analysis, KFF finds that 3.6